Aruna BIO Establishes Stroke Advisory Board to Advance Lead Program, AB126 into the Clinic
BOSTON and ATHENS, Ga., March 04, 2024 (GLOBE NEWSWIRE) -- Aruna Bio, Inc., a leader in neural exosome-based therapeutics for the treatment of neurodegenerative diseases, is pleased to announce the formation of its Stroke Advisory Board (SAB). Comprising distinguished experts in fields of neurology, stroke research, and clinical development, the board underscores Aruna Bio’s commitment to advancing its clinical development program with unparalleled expertise.
- Comprising distinguished experts in fields of neurology, stroke research, and clinical development, the board underscores Aruna Bio’s commitment to advancing its clinical development program with unparalleled expertise.
- The newly established board features renowned figures in the medical and scientific community, each bringing a wealth of knowledge and experience to Aruna Bio.
- “AB126 is making history with the first exosome therapy to enter human clinical trials for a neurological condition,” said Stephen From, Chief Executive Officer at Aruna Bio.
- “This represents a significant step forward in our quest to transform the treatment landscape for stroke and other neurodegenerative diseases.